By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Galapagos NV 

Industriepark Mechelen Noord I, Zone L
Generaal De Wittelaan 11 A
Mechelen    B-2800  Belgium
Phone: 32-15-34-29-00 Fax: 32-15-34-29-01



Company News
Galapagos (GLPG.BR) To Advance Filgotinib To Phase 3 In Rheumatoid Arthritis 9/25/2015 9:59:32 AM
AbbVie (ABBV) Walks Away from $1.4 Billion Arthritis Deal with Galapagos (GLPG.BR) to Develop Its Own Drug Instead 9/25/2015 7:01:55 AM
Galapagos (GLPG.BR) Presents Promising Pre-Clinical And Phase 1 Results With Autotaxin Inhibitor GLPG1690 At ERS 9/22/2015 9:18:16 AM
Galapagos (GLPG.BR) Release: Patient Recruitment Completed In FITZROY Phase 2 Crohn's Disease Study With Filgotinib 8/6/2015 8:33:00 AM
Galapagos (GLPG.BR) On Track To Deliver On Pipeline In Second Half 2015 8/6/2015 8:22:02 AM
Galapagos (GLPG.BR)' Selective JAK1 Inhibitor Filgotinib Meets Key Efficacy Endpoints, Shows ACR70 Responses Up To 39%, And Maintains Safety Profile After 24 Weeks Of Treatment In DARWIN 1 Phase 2B Study 7/30/2015 8:57:06 AM
Galapagos (GLPG.BR) Licenses Organoid Technology From The HUB Foundation For Use In Cystic Fibrosis And IBD Research 7/15/2015 11:31:02 AM
Galapagos (GLPG.BR) Raises €4.4 Million Through Warrant Exercises 6/22/2015 8:46:03 AM
Galapagos (GLPG.BR) Completes Recruitment For ORIGIN Phase 2 Trial With GLPG1205 In Ulcerative Colitis Patients 6/18/2015 9:36:52 AM
AbbVie (ABBV) And Galapagos (GLPG.BR) Present Cystic Fibrosis Corrector And Potentiator Screening Approach At ECFS Conference 6/15/2015 9:29:26 AM